These observations further reflect the situation in non-small cell lung cancer patients, where treatment with inhibitors of the HGF pathway in combination with EGFR inhibitors has been suggested to serve as a better treatment strategy than treatment with either inhibitor alone[21]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.